Depression is common in people with schizophrenia and is associated with substantial problems including an increased risk of suicide. Many clinicians use antidepressant drugs in addition to anti-psychotics in order to treat depression. This review identified eleven randomised controlled trials that compared antidepressants with a placebo in people with schizophrenia who also had depression. There was some evidence that antidepressants did lead to an improvement in global outcome, but the small number of studies providing usable data and their poor quality, suggest that this evidence should be interpreted with caution. At present, there is no convincing evidence either to support or refute the use of antidepressants in treating depression in people with schizophrenia. Further well-designed, conducted and reported research is needed in this area.

We reviewed the evidence about the effect of motivational interviewing (MI), a way of counselling to bring out and strengthen reasons for changing behaviour, for preventingalcohol misuse in young people.

A summary of the Clinical Practice Guidelines: Depression in adolescents and young adults

The first-line management for borderline personality disorder is psychosocial treatment, not drugs.

Depression is a mood state that is characterised by significantly lowered mood and a loss of interest or pleasure in activities that are normally enjoyable. Such depressed mood is a common and normal experience in the population. However, a major depressive episode can be distinguished from this `normal’ depression by its severity, persistence, duration, and the presence of characteristic symptoms (e.g., sleep disturbances).